Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Wheeler, C M, Skinner, S R, Rowena Del Rosario-Raymundo, M, Garland, S M, Chatterjee, A, Lazcano-Ponce, E, Salmeron, J, McNeil, S, Stapleton, J T, Bouchard, C, Martens, M G, Money, D M, Quek, S C, Romanowski, B, Vallejos, C S, ter Harmsel, B, Prilepskaya, V, Fong, K L, Kitchener, H, Minkina, G, Lim, Y K T, Stoney, T, Chakhtoura, N, Cruickshank, M E, Savicheva, A, da Silva, D P, Ferguson, M, Molijn, A C, Quint, W G V, Hardt, K, Descamps, D, Suryakiran, P V, Karkada, N, Geeraerts, B, Dubin, G, Struyf, F & VIVIANE Study Group 2016, 'Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study', Lancet Infectious Diseases, vol. 16, no. 10, pp. 1154-1168. https://doi.org/10.1016/S1473-3099(16)30120-7